Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01724866 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer
A Phase 2 study, sponsored by Spectrum Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 148
- Enrollment target
NCT01724866 is a Phase 2 study that has completed, run by Spectrum Pharmaceuticals. The registered enrollment target is 148 participants.
The verdict
NCT01724866, a Phase 2 study, has completed, sponsored by Spectrum Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 148 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effect of test doses of SPI-2012 on the duration of severe neutropenia (DSN) during Cycle 1 in participants with breast cancer who are candidates for adjuvant or neoadjuvant chemotherapy.
Interventions
- DRUG Cyclophosphamide
- DRUG Docetaxel
- DRUG Pegfilgrastim
- DRUG SPI-2012
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2013-03-25 |
| Est. Completion | 2014-08-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01724866
The ClinicalTrials.gov registry entry for NCT01724866 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spectrum Pharmaceuticals, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT01724866 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01724866 about?
NCT01724866 is a clinical study titled "Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer". The purpose of this study is to assess the effect of test doses of SPI-2012 on the duration of severe neutropenia (DSN) during Cycle 1 in participants with breast cancer who are candidates for adjuvant or neoadjuvant chemotherapy.
What is the current status of trial NCT01724866?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 148 participants. The study started on 2013-03-25. Estimated completion is 2014-08-12.
What interventions are being tested in trial NCT01724866?
The interventions under investigation include: Cyclophosphamide (DRUG), Docetaxel (DRUG), Pegfilgrastim (DRUG), SPI-2012 (DRUG).
Who is sponsoring clinical trial NCT01724866?
This trial is sponsored by Spectrum Pharmaceuticals, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.